Skip to main content

Equibles does not estimate personal net worth.

Get an email with a short summary when AN2 Therapeutics, Inc. publishes a filing, an earnings call transcript or a press release.

Get ANTX alerts

About Lucy Day

Lucy Day is recorded as Chief Accounting Officer at AN2 Therapeutics, Inc. (ANTX) since September 1, 2023 and CFO at AN2 Therapeutics, Inc. (ANTX). The newest filing on record that lists Lucy Day as CFO at AN2 Therapeutics, Inc. (ANTX) is dated April 22, 2026. AN2 Therapeutics, Inc. reported in an 8-K filed September 8, 2023 that Lucy Day was appointed Principal Accounting Officer, effective September 1, 2023. The proxy statement of AN2 Therapeutics, Inc. reports total compensation of $774,336 for Lucy Day in fiscal 2025, including a base salary of $447,200. Disclosed compensation is on record for 4 fiscal years. AN2 Therapeutics, Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at AN2 Therapeutics, Inc. includes Eric Easom (CEO and Board Member), Josh Eizen (COO), Joshua Eizen (COO and General Counsel) and 7 others.

“On September 1, 2023, the Company’s Board of Directors appointed Lucy Day, the Company’s current Chief Financial Officer and Principal Financial Officer, to also serve as the Company’s Principal Accounting Officer effective as of September 1, 2023.”
AN2 Therapeutics, Inc. Form 8-K, filed September 8, 2023 · Read the filing

Affiliation history

Company network

Current role

Biotechnology · Healthcare

CFO, Chief Accounting Officer

2023-09-01–present

Leadership on record at AN2 Therapeutics, Inc.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2025 AN2 Therapeutics, Inc. (ANTX) $447,200 $774,336
2024 AN2 Therapeutics, Inc. (ANTX) $447,200 $812,699
2023 AN2 Therapeutics, Inc. (ANTX) $430,000 $1,524,458
2022 AN2 Therapeutics, Inc. (ANTX) $379,934 $1,328,603

Recent activity